Rectal cancer

Critical Reviews in Oncology/Hematology

Volumn 70, Issue 2, 2009, Pages 160-182

  Zampino, Maria Giulia ^a   Labianca, Roberto ^b   Beretta, Giordano D ^c   Magni, Elena ^a   Gatta, Gemma ^d   Leonardi, Maria Cristina ^a   Chiappa, Antonio ^a   Biffi, Roberto ^a   de Braud, Filippo ^a   Wils, Jacques ^e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c S Orsola Hospital   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

Rectal cancer; Strategy; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN;

BLEEDING; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; CONTINUOUS INFUSION; DIAGNOSTIC TEST; DIARRHEA; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PELVIS CANCER; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PREVALENCE; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RECTUM CANCER; RECTUM RESECTION; RECURRENT CANCER; REVIEW; RISK FACTOR; STOMATITIS; SURVIVAL TIME; THROMBOSIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 63549127178     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.10.010     Document Type: Review

References (191)

1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer, vol. VIII. IARC Scient. Publ. No. 155, 2002.
2. Ferlay J, Bray F, Pisani P, Parkin DM. Parkin. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0 IARCPress, Lyon, 2004.
3. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 37 Suppl. 8 (2001) S4-66
4. Crocetti E., Capocaccia R., Casella C., et al. Population-based incidence and mortality cancer trends (1986-1997) from the network of Italian cancer registries. Eur J Cancer Prev 13 (2004) 287-295
5. Berrino F., De A.R., Sant M., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol 8 (2007) 773-783
6. Engholm G., Kejs A.M., Brewster D.H., et al. Colorectal cancer survival in the Nordic countries and the United Kingdom: excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000. Int J Cancer 121 (2007) 1115-1122
7. Micheli A., Mugno E., Krogh V., et al. Cancer prevalence in European registry areas. Ann Oncol 13 (2002) 840-865
8. Grande E., Inghelmann R., Francisci S., et al. Regional estimates of colorectal cancer burden in Italy. Tumori 93 (2007) 352-359
9. Kwak E.L., and Chung D.C. Hereditary colorectal cancer syndromes: an overview. Clin Colorectal Cancer 6 (2007) 340-344
10. Shimizu H., Mack T.M., Ross R.K., and Henderson B.E. Cancer of the gastrointestinal tract among Japanese and white immigrants in Los Angeles County. J Natl Cancer Inst 78 (1987) 223-228
11. In: Stewart B.W., and Kleihus P. (Eds). World Cancer Report (2003), IARC Press, Lyon
12. WCRF & AICR. World Cancer Research Fund and American Institute for Cancer Research. Food, Nutrition and Prevention of Cancer: a Global Perspective. American Institute of Cancer Research, Washington, book 1997, 0.
13. Park Y., Subar A.F., Kipnis V., et al. Fruit and vegetable intakes and risk of colorectal cancer in the NIH-AARP diet and health study. Am J Epidemiol 166 (2007) 170-180
14. IWG. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Fruit and vegetables (2003), IARC Press, Lyon
15. Bingham S.A., Day N.E., Luben R., et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 361 (2003) 1496-1501
16. Schatzkin A., Mouw T., Park Y., et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP Diet and Health Study. Am J Clin Nutr 85 (2007) 1353-1360
17. Ferrari P., Jenab M., Norat T., et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 121 (2007) 2065-2072
18. Gonzalez C.A., and Riboli E. Diet and cancer prevention: where we are, where we are going. Nutr Cancer 56 (2006) 225-231
19. Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 10 (2001) 725-731
20. Baxter N.N., Tepper J.E., Durham S.B., Rothenberger D.A., and Virnig B.A. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 128 (2005) 819-824
21. Ahmed R.L., Schmitz K.H., Anderson K.E., Rosamond W.D., and Folsom A.R. The metabolic syndrome and risk of incident colorectal cancer. Cancer 107 (2006) 28-36
22. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 (2004) 991-1004
23. Imperiale T.F., Wagner D.R., Lin C.Y., et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 346 (2002) 1781-1785
24. Mandel J.S., Church T.R., Ederer F., and Bond J.H. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91 (1999) 434-437
25. Winawer S., Fletcher R., Rex D., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124 (2003) 544-560
26. Lurie J.D., and Welch H.G. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 91 (1999) 1641-1646
27. Selby J.V., Friedman G.D., Quesenberry C.P.J., and Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326 (1992) 653-657
28. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;20(343):162-8.
29. ACCP. Advisory Committee on Cancer Prevention. Recommendations on cancer screening in the European union. Eur J Cancer 36 (2000) 1473-1478
30. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 328 (1987) 614-616
31. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 (1988) 525-532
32. Forrester K., Almoguera C., Han K., Grizzle W.E., and Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327 (1987) 298-303
33. Kinzler K.W., Nilbert M.C., Vogelstein B., et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251 (1991) 1366-1370
34. Broders A.C. The grading of carcinoma. Minn Med 8 (1925) 726-730
35. Dukes C.E. The classification of cancer of the rectum. J Pathol 35 (1932) 323-332
36. Qizilbash A.H. Pathologic studies in colorectal cancer. A guide to the surgical pathology examination of colorectal specimens and review of features of prognostic significance. Pathol Annu 17 (1982) 1-46
37. Jass J.R., Atkin W.S., Cuzick J., et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 10 (1986) 437-459
38. Bresalier R.A., Boland C.R., Itzkowitz S.H., and Kim Y.S. Basic gastrointestinal oncology. In: Kern Jr. F., and Blum Al (Eds). The gastroeneterology annual/2 (1989), Elsevier/North Holland. Book, Amsterdam 271-319
39. Moertel C.G., O'Fallon J.R., Go V.L., O'Connell M.J., and Thynne G.S. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 58 (1986) 603-610
40. Fletcher R.H. Carcinoembryonic antigen. Ann Intern Med 104 (1986) 66-73
41. Bresalier R.S., Boland C.R., and Kim Y.S. Characteristics of colorectal carcinoma cells with high metastatic potential. Gastroenterology 87 (1984) 115-122
42. Cohen A.M., Minsky B.D., and Schilsky R.L. Colon cancer. In: De Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 4th ed. (1993), JB Lippincott Company. Book, Philadelphia 929-977
43. Eisenberg B., DeCosse J.J., Harford F., and Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer 49 (1982) 1131-1134
44. Newland R.C., Chapuis P.H., Pheils M.T., and MacPherson J.G. The relationship of survival to staging and grading of colorectal carcinoma: a prospective study of 503 cases. Cancer 47 (1981) 1424-1429
45. Olson R.M., Perencevich N.P., Malcolm A.W., Chaffey J.T., and Wilson R.E. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 45 (1980) 2969-2974
46. UICC. UICC (International Union Against Cancer). TNM classification of malignant tumours. Sobin LH, Wittekind Ch, editors. 6th ed. New York, Chichester, Weinheim, Brisbane, Singapore, Toronto: Wiley-Liss, Book, 2002.
47. Zinkin L.D. A critical review of the classifications and staging of colorectal cancer. Dis Colon Rectum 26 (1983) 37-43
48. Snady H., and Merrick M.A. Improving the treatment of colorectal cancer: the role of EUS. Cancer Invest 16 (1998) 572-581
49. Dershaw D.D., Enker W.E., Cohen A.M., and Sigurdson E.R. Transectal ultrasonography of rectal carcinoma. Cancer 66 (1990) 2336-2340
50. Butch R.J., Stark D.D., Wittenberg J., et al. Staging rectal cancer by MR and CT. AJR Am J Roentgenol 146 (1986) 1155-1160
51. Guinet C., Buy J.N., Ghossain M.A., et al. Comparison of magnetic resonance imaging and computed tomography in the preoperative staging of rectal cancer. Arch Surg 125 (1990) 385-388
52. Beets-Tan R.G., Beets G.L., Vliegen R.F., et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 357 (2001) 497-504
53. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007;243:132-9.
54. Gearhart S.L., Frassica D., Rosen R., et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 13 (2006) 397-404
55. Levi F., Lucchini F., Boyle P., Negri E., and La Vecchia C. Cancer incidence and mortality in Europe 1988-1992. J Epidemiol Biostat 3 (1998) 295-361
56. Fernandez E., La V.C., Gonzalez J.R., et al. Converging patterns of colorectal cancer mortality in Europe. Eur J Cancer 41 (2005) 430-437
57. Steinberg S.M., Barkin J.S., Kaplan R.S., and Stablein D.M. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer 57 (1986) 1866-1870
58. Hermanek P., Hutter R.V., and Sobin L.H. Prognostic grouping: the next step in tumor classification. J Cancer Res Clin Oncol 116 (1990) 513-516
59. Bell S.M., Scott N., Cross D., et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104 (1993) 57-64
60. Deans G.T., Parks T.G., Rowlands B.J., and Spence R.A. Prognostic factors in colorectal cancer. Br J Surg 79 (1992) 608-613
61. Watson A.J., Merritt A.J., Jones L.S., et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 73 (1996) 889-895
62. Arbman G., Nilsson E., Hallbook O., and Sjodahl R. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 83 (1996) 375-379
63. de Haas-Kock D.F., Baeten C.G., Jager J.J., et al. Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 83 (1996) 781-785
64. Lee S.H., Hernandez D.A., Finne C.O., Madoff R.D., and Garcia-Aguilar J. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision. Dis Colon Rectum 48 (2005) 2249-2257
65. Filella X., Molina R., Grau J.J., et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 216 (1992) 55-59
66. Fitzgerald S.D., Longo W.E., Daniel G.L., and Vernava A.M. Advanced colorectal neoplasia in the high-risk elderly patient: is surgical resection justified?. Dis Colon Rectum 36 (1993) 161-166
67. Lorchel F., Peignaux K., Crehange G., et al. Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol 31 (2007) 436-441
68. Stephenson K.R., Steinberg S.M., Hughes K.S., et al. Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 208 (1988) 679-687
69. Voogt P.J., van d V., Brand A., et al. Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer 59 (1987) 836-843
70. Heiss M.M., Mempel W., Delanoff C., et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 12 (1994) 1859-1867
71. Busch O.R., Hop W.C., Hoynck P.M., Marquet R.L., and Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 328 (1993) 1372-1376
72. Donohue J.H., Williams S., Cha S., et al. Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study. J Clin Oncol 13 (1995) 1671-1678
73. Jagoditsch M., Pozgainer P., Klingler A., and Tschmelitsch J. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum 49 (2006) 1116-1130
74. Kohne C.H., Cunningham D., Di C.F., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13 (2002) 308-317
75. Kemeny N., Kemeny M., and Lawrence T.S. Liver metastases. In: Abeloff M.D., Armitage J.O., and Lichter S.A. (Eds). Clinical oncology (1995), Churchill Livingstone, Book, New York 679-707
76. Wang J.Y., Lu C.Y., Chu K.S., et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39 (2007) 245-250
77. Allen-Mersh T.G., McCullough T.K., Patel H., et al. Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br J Surg 94 (2007) 96-105
78. Khair G., Monson J.R., and Greenman J. Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. Dis Colon Rectum 50 (2007) 1188-1203
79. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 (1997) 19-23
80. Jakob C., Liersch T., Meyer W., et al. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. Am J Surg Pathol 30 (2006) 1169-1174
81. Buyse M., Thirion P., Carlson R.W., et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis Group in Cancer. Lancet 356 (2000) 373-378
82. Roh M.S., Petrelli N., Wieand S., et al. Phase III Randomized Trial of Preoperative Versus Postoperative Multimodality Therapy in Patients with Carcinoma of the Rectum (NSABP R-03). Proc ASCO 20 (2001) 123a
83. Rodel C., Grabenbauer G.G., Papadopoulos T., et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21 (2003) 3098-3104
84. Stein B.L., and Coller J.A. Management of malignant colorectal polyps. Surg Clin North Am 73 (1993) 47-66
85. Seitz U., Bohnacker S., and Seewald S./E.-A. Is endoscopic polyoectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 47 11 (2004) 1789-1796
86. Heimann T.M., Szporn A., Bolnick K., and Aufses A.H.J. Local recurrence following surgical treatment of rectal cancer. Comparison of anterior and abdominoperineal resection. Dis Colon Rectum 29 (1986) 862-864
87. Williams N.S. The rationale for preservation of the anal sphincter in patients with low rectal cancer. Br J Surg 71 (1984) 575-581
88. Wolmark N., and Fisher B. An analysis of survival and treatment failure following abdominoperineal and sphincter-saving resection in Dukes' B and C rectal carcinoma. A report of the NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. Ann Surg 204 (1986) 480-489
89. Grotz R., Pemberton J.H., and Gunderson L.L. Treatment results with radical surgery. In: Cohen A.M., Winawer S.J., Friedman M.A., and Gunderson L.L. (Eds). Cancer of the Colon Ractum and Anus (1995), MacGraw-Hill Inc., Book, New York 605-614
90. Paty P.B., Enker W.E., Cohen A.M., Minsky B.D., and Friedlander-Klar H. Long-term functional results of coloanal anastomosis for rectal cancer. Am J Surg 167 (1994) 90-94
91. Wagman R., Minsky B.D., Cohen A.M., Guillem J.G., and Paty P.P. Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. Int J Radiat Oncol Biol Phys 42 (1998) 51-57
92. Billingham R.P. Conservative treatment of rectal cancer. Extending the indications. Cancer 70 (1992) 1355-1363
93. DeCosse J.J., Wong R.J., Quan S.H., Friedman N.B., and Sternberg S.S. Conservative treatment of distal rectal cancer by local excision. Cancer 63 (1989) 219-223
94. Bailey H.R., Huval W.V., Max E., et al. Local excision of carcinoma of the rectum for cure. Surgery 111 (1992) 555-561
95. Papillon J., and Berard P. Endocavitary irradiation in the conservative treatment of adenocarcinoma of the low rectum. World J Surg 16 (1992) 451-457
96. Russell A.H., Harris J., Rosenberg P.J., et al. Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02. Int J Radiat Oncol Biol Phys 46 (2000) 313-322
97. Sitzler P.J., Seow-Choen F., Ho Y.H., and Leong A.P. Lymph node involvement and tumor depth in rectal cancers: an analysis of 805 patients. Dis Colon Rectum 40 (1997) 1472-1476
98. Willett C.G., Compton C.C., Shellito P.C., and Efird J.T. Selection factors for local excision or abdominoperineal resection of early stage rectal cancer. Cancer 73 (1994) 2716-2720
99. Steele Jr. G.D., Herndon J.E., Bleday R., et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol 6 (1999) 433-441
100. Kodner I.J., Gilley M.T., Shemesh E.I., et al. Radiation therapy as definitive treatment for selected invasive rectal cancer. Surgery 114 (1993) 850-856
101. Maingon P., Guerif S., Darsouni R., et al. Conservative management of rectal adenocarcinoma by radiotherapy. Int J Radiat Oncol Biol Phys 40 (1998) 1077-1085
102. Gerard J.P., Chapet O., Nemoz C., et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 22 (2004) 2404-2409
103. Tepper J.E. The necessity of radiation therapy in the adjuvant therapy of patients with low-stage rectal cancer. ASCO educational book (2007) pp. 204-6
104. Gunderson L.L., Nelson H., Martenson J.A., et al. Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation ±5-FU. Int J Radiat Oncol Biol Phys 37 (1997) 601-614
105. Nakfoor B.M., Willett C.G., Shellito P.C., Kaufman D.S., and Daly W.J. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg 228 (1998) 194-200
106. NIH. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264 (1990) 1444-1450
107. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331 (1994) 502-507
108. Gerard J.P., Conroy T., Bonnetain F., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucoverin in T3-T4 rectal cancer: results of FCD 9203. JCO 24 October (28) (2006) 4620-4625
109. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. NEJM 355 September (11) (2006) 1114-1123
110. SRCT. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336 (1997) 980-987
111. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
112. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
113. Smalley S.R., Benedetti J., Williams S., et al. Intergroup 0144 - phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT + PVI vs. bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc ASCO 22 (2003) 251
114. Bosset J.F., Mantion G., Lorchel F., et al. Adjuvant and neoadjuvant radiation therapy for rectal cancer. Semin Oncol 27 (2000) 60-65
115. Minsky B., Cohen A., Enker W., et al. Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer 73 (1994) 273-280
116. Minsky B.D., Cohen A.M., Kemeny N., et al. The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 71 (1993) 3486-3492
117. Chari R.S., Tyler D.S., Anscher M.S., et al. Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 221 (1995) 778-786
118. Grann A., Minsky B.D., Cohen A.M., et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 40 (1997) 515-522
119. Rich T.A., Skibber J.M., Ajani J.A., et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 32 (1995) 1025-1029
120. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., and Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 5 (1999) 2948-2953
121. Glynne-Jones R., Dunst J., and Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. Ann Oncol 17 (2006) 361-371
122. Cassidy J., Tabernero J., Twelves C., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 (2004) 2084-2091
123. Glynne-Jones R., Sebag-Montefiore D., Maughan T.S., Falk S.J., and McDonald A.C. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17 (2006) 50-56
124. Machiels J.P., Duck L., Honhon B., et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16 (2005) 1898-1905
125. Chau I., Brown G., Cunningham D., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24 (2006) 668-674
126. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol 11 Suppl. 3 (2000) 29-36
127. Adson M.A., van Heerden J.A., Adson M.H., Wagner J.S., and Ilstrup D.M. Resection of hepatic metastases from colorectal cancer. Arch Surg 119 (1984) 647-651
128. Coppa G.F., Eng K., Ranson J.H., Gouge T.H., and Localio S.A. Hepatic resection for metastatic colon and rectal cancer. An evaluation of preoperative and postoperative factors. Ann Surg 202 (1985) 203-208
129. Scheele J., Stangl R., and Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77 (1990) 1241-1246
130. Scheele J., Stangl R., Altendorf-Hofmann A., and Gall F.P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110 (1991) 13-29
131. Wagman L.D., Kemeny M.M., Leong L., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8 (1990) 1885-1893
132. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
133. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
134. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
135. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
136. Grothey A., Deschler B., Kroening H., et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc ASCO 21 (2002) 129a
137. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
138. Hurwitz H., Fehrenbacher L., Cartwright T., et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 22 (2003) 3646a
139. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
140. Pedersen I.K., Burcharth F., Roikjaer O., and Baden H. Resection of liver metastases from colorectal cancer. Indications and results. Dis Colon Rectum 37 (1994) 1078-1082
141. Steele G.J., Bleday R., Mayer R.J., et al. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 9 (1991) 1105-1112
142. Fong Y., Cohen A.M., Fortner J.G., et al. Liver resection for colorectal metastases. J Clin Oncol 15 (1997) 938-946
143. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
144. Hamady Z.Z., Cameron I.C., Wyatt J., et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1 cm rule. Eur J Surg Oncol 32 (2006) 557-563
145. Harmon K.E., Ryan J.A.J., Biehl T.R., and Lee F.T. Benefits and safety of hepatic resection for colorectal metastases. Am J Surg 177 (1999) 402-404
146. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005) 715-722 discussion
147. Adam R., Bismuth H., Castaing D., et al. Repeat hepatectomy for colorectal liver metastases. Ann Surg 225 (1997) 51-60
148. Nordlinger B., Vaillant J.C., Guiguet M., et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 12 (1994) 1491-1496
149. Petrowsky H., Gonen M., Jarnagin W., et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235 (2002) 863-871
150. Adam R., Pascal G., Azoulay D., et al. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 238 (2003) 871-883
151. Morise Z., Sugioka A., Fujita J., et al. Does repeated surgery improve the prognosis of colorectal liver metastases?. J Gastrointest Surg 10 (2006) 6-11
152. Girard P., Ducreux M., Baldeyrou P., et al. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 14 (1996) 2047-2053
153. McAfee M.K., Allen M.S., Trastek V.F., et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 53 (1992) 780-785
154. Okumura S., Kondo H., Tsuboi M., et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 112 (1996) 867-874
155. Pfannschmidt J., Muley T., Hoffmann H., and Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 126 (2003) 732-739
156. Saito Y., Omiya H., Kohno K., et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 124 (2002) 1007-1013
157. Vogelsang H., Haas S., Hierholzer C., et al. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91 (2004) 1066-1071
158. Langer B., Bleiberg H., Labianca R., et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc ASCO 21 (2002) 149a
159. Nordlinger B., Sorbye H., Collette L., et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. Proc ASCO 25 no. 18S (2007) LBA5
160. Thomas D.S., Nauta R.J., Rodgers J.E., et al. Intraoperative high-dose rate interstitial irradiation of hepatic metastases from colorectal carcinoma. Results of a phase I-II trial. Cancer 71 (1993) 1977-1981
161. Berber E., Pelley R., and Siperstein A.E. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23 (2005) 1358-1364
162. McKay A., Dixon E., and Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 93 (2006) 1192-1201
163. Cassidy J., Twelves C., Van Cutsem E., et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13 (2002) 566-575
164. Hoff P.M., Royce M., Medgyesy D., Brito R., and Pazdur R. Oral fluoropoyrimidines. Semin Oncol 26 (1999) 640-646
165. Saif M.W. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 5 (2005) 89-100
166. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38 Suppl. 2 (2002) 15-20
167. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
168. Saltz L.B., Douillard J., Pirrotta N., et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs. F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc ASCO 19 (2000) 242a
169. Andre T., Bensmaine M.A., Louvet C., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17 (1999) 3560-3568
170. Bleiberg H., and de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25 Suppl. 5 (1998) 32-39
171. Cvitkovic E., and Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26 (1999) 647-662
172. de Gramont A., Vignoud J., Tournigand C., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33 (1997) 214-219
173. Sargent D.J., Niedzwiecki D., O'Connell M.J., and Schilsky R.L. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345 (2001) 144-145
174. Rothenberg M.L., Meropol N.J., Poplin E.A., Van Cutsem E., and Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19 (2001) 3801-3807
175. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
176. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
177. Grothey A., and Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23 (2005) 9441-9442
178. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676
179. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
180. Maindrault-Goebel F., Lledo G., Chibaudel B., et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO 25 no. 18S (2007) 166s
181. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
182. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO 25 (2007) 4028a
183. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
184. Lenz H.J., Mayer R.J., Gold P.J., et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc ASCO 22 (2004) 248
185. Eng C., Maurel J., Scheithauer W., et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Proc ASCO 25 no. 18S (2007) 164s
186. Freeman D.J., Juan T., Reiner M., et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7 May (3) (2008) 184-190
187. Van Cutsem E., Nowacki M., Lang I., et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc ASCO 25 (2007) 4000a
188. Pihl E., Hughes E.S., McDermott F.T., and Price A.B. Recurrence of carcinoma of the colon and rectum at the anastomotic suture line. Surg Gynecol Obstet 153 (1981) 495-496
189. Suzuki K., Dozois R.R., Devine R.M., et al. Curative reoperations for locally recurrent rectal cancer. Dis Colon Rectum 39 (1996) 730-736
190. NHS. Guidance on commissioning cancer cervices: improving outcomes in colorectal cancer. London: NSH Executive, Book 1997; 0.
191. Montague E.D., and Delclos L. Palliative radiotherapy in the management of metastatic disease. In: Fletcher G.H. (Ed). Textbook of radiotherapy. 3rd ed. (1995), Lea Febiger, Book, Philadelphia 943-948